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BACKGROUND Use of mechanical circulatory support (MCS) devices
in cardiogenic shock (CS), acute Myocardial Infarction (MI), high-risk
percutaneous coronary interventions (PCI) has been extensively
studied. High-risk surgical patients with valvular heart diseases un-
dergoing percutaneous treatment such as transcatheter aortic valve
replacement (TAVR) represent an emerging population which may
beneﬁt from short term use of MCS.
METHODS We analyzed data from Nationwide Inpatient Sample (2011
and 2012) using the ICD, 9th Revision, Clinical Modiﬁcation procedure
codes.
RESULTS A total of 1,794 TAVR procedures (375 hospitals in the US)
were identiﬁed of which 190 (10.6 %) utilized a MCS device (MCS
group) and 1,604 (89.4%) did not (non-MCS group). A higher per-
centage of patients in MCS group underwent trans-apical TAVR (54%
vs 13%, p<0.01), had AMI (6.4% vs. 2.1%, p<0.01), underwent percu-
taneous coronary intervention (5.4% vs. 2.1%, p<0.01), had cardiac
arrest (10% vs. 2.3%, p¼<0.01) (including ventricular ﬁbrillation: 8%
vs. 1%, p¼<0.01) and cardiogenic shock (16.8% vs. 2.9%, p<0.01)
when compared to the non-MCS group. On the other hand the patients
in non-MCS group were older (71% vs. 37% >80 years old, p<0.01) and
had a higher mean Charlson’s comorbidity score (2.650.04 vs. 20.1,
p<0.01).The use of MCS devices with TAVR was associated with sig-
niﬁcant increase in the in-hospital mortality (14.9% vs. 3.5%, p<0.01).
The mean length (11.80.8 vs. 8.10.2 days, p<0.01) and cost
($68,9973,656 vs. $55,878653, p¼0.03) of hospitalization were also
signiﬁcantly higher in MCS group. Ventricular ﬁbrillation arrest, trans-
apical access for TAVR and cardiogenic shock, were the most signiﬁ-
cant predictors of MCS use during TAVR. In the multivariate model,
use of any MCS device was found to be an independent predictor of
increased mortality (OR 3.5, 95% CI 2.6-4.6, p<0.0001) and compli-
cations (OR 3.3, 95% CI 2.8-3.9, p<0.0001) Figure 1. The propensity
score matched analysis (n¼160 in each group) also showed a similar
result.CONCLUSIONS The unacceptably high rates of mortality and com-
plications coupled with a signiﬁcant increase in the length and cost of
hospitalization should raise concerns about utility of MCS devices
during TAVR in this prohibitive surgical risk population.
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BACKGROUND Intra-aortic balloon pump (IABP) is the most
commonly utilized mechanical support device in the cardiac cathe-
terization laboratories. The last decade has witnessed the develop-
ment and Food and Drug Administration approval of alternative
percutaneous ventricular assist devices (PVADs) such as Impella
(Abiomed, Danvers, MA, USA) and TandemHeart (Cardiac Assist, Inc.,
Pittsburgh, PA). Despite the lack of clear evidence of superiority, the
utilization of PVAD has increased substantially in the last decade. The
present study was designed to provide further insights into PCIs
performed with hemodynamic support (IABP or PVAD) using the na-
tion’s largest available hospitalization database.
METHODS This was a cross sectional study using the Nationwide
Inpatient Sample database between the years 2008-2012. Procedures
were identiﬁed through appropriate clinical modiﬁcation of Interna-
tional Classiﬁcation of Diseases, ninth edition (ICD-9-CM) codes for
PCI, PVAD and IABP placement. We used propensity-scoring method
to establish matched cohorts in order to control for imbalances of
patients’ and hospitals’ characteristics between the studied groups
which may have inﬂuenced the primary outcome.
RESULTS A total of 18,094 procedures were identiﬁed over the ﬁve
year study period between 2008 through 2012. IABP was the most
commonly utilized hemodynamic support device (93%, n¼16, 803)
whereas 6% (n¼1069) were performed with PVADs and 1% (n¼222)
utilized both IABP and PVAD. Patients in the PVAD group were older
in age and had greater burden of co-morbidities when compared to
those in the IABP group. A higher proportion of patients in the PVAD
group were admitted emergently whereas IABP group had higher
percentage of patients with cardiac arrest. We observed an in-hospital
mortality rate of 20.1% for IABP, 12% with PVAD and 41% in IABP+P-
VAD group. Overall complications rate for this patient population was
36% for IABP vs. 26% for PVAD vs. 52% for the IABP+PVAD group. The
use of PVADs was a signiﬁcant predictor of reduced mortality (OR
0.16, 0.07-0.36, p<0.0001, as well as complications rate (OR 0.45,
0.32-0.64, p<0.001) when compared to IABP only in the sub-group of
patients without AMI or cardiogenic shock. Propensity score matched
analysis also showed a signiﬁcantly lower mortality (9.9% vs. 15.1%;
OR 0.62, 0.55-0.71, p<0.001) and complications (24.8% vs. 31.5%; OR
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to IABP.
CONCLUSIONS This is the largest and the most contemporary study
on the use of hemodynamic support which demonstrates signiﬁcantly
reduced mortality and complications with PVADs when compared to
IABP in patients undergoing PCI and this effect is largely driven by the
improved outcomes in non-AMI and non-cardiogenic shock patients.
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BACKGROUND Impella (Abiomed Inc, Danvers, Mass) is a percuta-
neous left ventricular assist device used in the setting of high-risk
coronary intervention, cardiogenic shock and ablation procedures.
METHODS This is a single center study evaluating the use of Impella
in high-risk patients undergoing PCI. Impella use was classiﬁed as
‘elective’ in patients who were identiﬁed to be high-risk or in shock
prior to the procedure (Group 1, N¼ 129). Patients who received an
Impella as a result of an acute hemodynamic compromise or proce-
dural complication were classiﬁed as ‘emergent’ (Group 2, N¼ 57). The
primary endpoint was a composite MACE of in hospital mortality;
vascular complications and BARC deﬁned bleeding.
RESULTS Between 2010 and 2014, 187 high-risk patients underwent
Impella placement. The baseline demographics of both groups were
similar (Fig 1). The mean age was 67.5 years (p¼ns). The mean ejection
fraction was 28.3% (p¼ns). Elective Impella use (group 1) was
associated with more complete revascularization (2.3 vs 1.3 stents,
p<0.001), successful weaning and explant of Impella at end of
procedure (79% vs 10%, p<0.001) and successful hemostasis with
perclose in preclose fashion (81% vs 8%, p<0.001). The MACE rate
in Group 1 was 24% v/s 67% in Group 2 (p<0.001) (Table 1). The
drivers of this difference in MACE were in-hospital mortality (9% v/s
49%; p<0.001) and need for more blood transfusions in the
emergent group (1.3% v/s 2.9;p¼0.009). In multivariate analysis,
independent predictors of in hospital MACE events were emergent
Impella placement (OR 6.14, p<0.001), baseline ejection fraction and
removal of Impella at the end of the procedure (Fig 1).Outcomes Elective Emergent p-valueMACE 24 % (32) 67 % (41) <0.001Any Bleeding 23 % (30) 34 % (21) 0.09BARC major or life
threatening
bleeding15 % (19) 31 % (19) 0.48In-hospital death 9 % (12) 49 % (30) <0.001Vascular
Complications15 % (20) 16 % (10) 0.84Units of PRBCs infused 1.3  3.7 2.9  4.6 0.009
Bleeding at implant
site8 % (11) 15 % (9) 0.18Duration of procedure
(minutes  SD)
143  60 113  48 0.001Median length of stay
(Days  SD)
6  9.2 5  11 0.88CONCLUSIONS The real world use of the Impella mimics use in the
PROTECT 2 trial with similar baseline demographics and ejection
fraction. The elective use is largely in the setting of HRPCI whereas
the emergent use is largely in the setting of cardiogenic shock. In
hospital mortality and MACE in the emergent setting remain very high
whereas in the elective setting especially with early device explant,
the in-hospital mortality and MACE rates are low.
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BACKGROUND IABP is a widely used circulatory support device. The
IABP-SHOCK II trial (2012) showed that IABP did not improve 30-day
mortality. US and European guidelines have subsequently revised
their recommendations for IABP from class I to IIa and IIb, respec-
tively. Despite limited evidence, peripheral VA-ECMO is an estab-
lished treatment for refractory cardiogenic shock (CS). Current
guidelines have a IIb recommendation for use. The aim of this retro-
spective, observational analysis was to study the contemporary usage
patterns and outcomes of IABP, as well as to understand our early
experience with VA-ECMO in patients who have initially received an
IABP, at a single center.
METHODS From January 2010 to September 2014, we retrospec-
tively analyzed the Cardiac Catheterization database at Liverpool
Hospital, Sydney, for consecutive patients receiving an IABP,
including those who subsequently required VA-ECMO during the
same admission.
RESULTS Among 219 patients, who received a total of 222 IABP in-
sertions (mean age 65.911.8 years, range 23.1-91.4 years), 49 (22%)
were women; 38 (17%) had diabetes mellitus; 35 (16%) had left main
stenosis >70%; 29 (13%) were administered a GPIIbIIIa antagonist; 60
(27.4%) died during hospitalization. The 7.5Fr 40cc Sensation cath-
eter (Maquet, USA) was most commonly utilized (146 cases, 65.7%).
Mean dwell time was 46.143.7 hours (range 0.3–240 hours). Com-
plications occurred in 9 cases (2 severe access site bleeding requiring
transfusion, 1 minor access site bleeding, 4 leg ischemia, 1 access
related sepsis,1 IABP related mortality). CS was the commonest
indication and had high in-hospital mortality (46.3%). A total of 7
patients required VA-ECMO (mean age 64.79.6 years, range 49 to
75.2 years), 2 were women; 4 had diabetes mellitus. VA-ECMO was
initiated before left main stenting in 2 cases, and after revasculari-
zation in the others. IABP was left in situ in 3 patients. VA-ECMO was
